This application note explores optimized culturing conditions for precision-cut slices (PCS) of non-small cell lung carcinoma ...

Oncolytic viruses are a very promising class of therapeutic agents, with a broad range of types. In this exclusive interview ...

Vasoactive Intestinal Peptide (VIP) is an intriguing neuropeptide with a wide range of potential biological impacts, primarily hypothesized in tissues, cells, and internal systems. Since its discovery ...

Gastric cancer (GC) is a lethal malignancy with worldwide occurrence, and is considered endemic in eastern Asian, eastern ...

Our additional preliminary studies demonstrate that dual targeting of multiple myeloma cells and BM-CAFs by CAR-T cells is ...

Filippo Veglia, Ph.D., of Wistar’s Genome Regulation and Cell Signaling Program, discusses the most lethal form of brain ...

A new drug strategy that regulates the tumor immune microenvironment may transform a tumor that resists immunotherapy into a susceptible one, according to a new study.

Topline data from Phase 2 CM24 pancreatic cancer trial expected by the end of 2024 New CM24 biomarkers data presented during the third quarter of 2024 including two predicting serum biomarkers identif ...

Tumors find different ways to avoid immune cell detection and proliferate in their environment. Antitumor immune cells will ...

Over the last 2 decades, significant progress has been made in our understanding of the genomics, tumor immune ...

A new drug strategy that regulates the tumor immune microenvironment may transform a tumor that resists immunotherapy into a ...

For unresectable or metastatic liver cancer, the TPST-1120-301 trial of amezalpat combination therapy has received a “Study ...